Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 3115 • 2016 ACR/ARHP Annual Meeting
Reconsidering the Juvenile Idiopathic Arthritis Core Set: How Patients and Caregivers Define Disease Activity
Jennifer R. Horonjeff¹, Susan Thornhill², Daniel B. Horton³, Jennifer N. Stinson⁴, Anjali Fortna⁵, Stephanie Luca⁶, Arlene Vinci⁷, Laura C. Marrow⁸, Emily L. Creek⁷, Meredith Riebschleger⁹, Alessandro Consolaro¹⁰, Jane Munro¹¹, Vibeke Strand¹², Clifton Bingham III¹³ and Esi Morgan¹⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Thornhill Associates, Hermosa Beach, CA, ³Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁴Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Columbia University Medical Center, New York, NY, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Consumer Health, Arthritis Foundation, Atlanta, GA, ⁸Arthritis Foundation, Atlanta, GA, ⁹Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ¹⁰Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ¹¹Rheumatology, Royal Children's Hospital, Parkville, Australia, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³Divisions of Rheumatology and Allergy, Department of Medicine, Johns Hopkins University, Johns Hopkins University, Baltimore, MD, ¹⁴Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: The current JIA Core Set (ACR Pediatric 30) contains items that should be assessed in clinical trials for children with JIA. It was developed…
Abstract Number: 407 • 2016 ACR/ARHP Annual Meeting
Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Stephanie J.W.Shoop^1,2, Kimme L. Hyrich^3,4, Suzanne M.M. Verstappen⁴, Wendy Thomson^5,6, Janet E. McDonagh⁷ and CAPS, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom
Background/Purpose: It is unclear which tool should measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is completed on the…
Abstract Number: 410 • 2016 ACR/ARHP Annual Meeting
Sleep and Its Relationship to Pain and Disease Activity in Turkish Children and Adolescent with Juvenile Idiopathic Arthritis
Ela Tarakci¹, Saime Nilay Baydogan¹, Kenan Barut², Amra Adrovic², Sezgin Sahin² and Ozgur Kasapcopur³, ¹Istanbul University, Faculty of Health Science, Division of Physiotherapy and Rehabilitation, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group of arthritis of unknown cause, which begin before 16 years of…
Abstract Number: 411 • 2016 ACR/ARHP Annual Meeting
Evaluating Levels of Activity and Health-Related Quality of Life in a Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Tommy Gerschman¹, Jordan Raugust², Julia Brooks³, Nicole Johnson¹, Nadia Luca¹, Rebeka Stevenson¹, Heinrike Schmeling⁴, Paivi Miettunen¹ and Susanne Benseler¹, ¹Pediatrics, University of Calgary, Calgary, AB, Canada, ²Department of Pediatrics, University of Calgary, Calgary, AB, Canada, ³Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Paediatrics, University of Calgary, Calgary, AB, Canada
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
Abstract Number: 416 • 2016 ACR/ARHP Annual Meeting
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
Ivan Foeldvari¹, Nicolino Ruperto¹, Daniel J Lovell², Gerd Horneff¹, Hans-Iko Huppertz³, Pierre Quartier⁴, Gabriele Simonini¹, Mareike Bereswill⁵, Jasmina Kalabic⁵, Alberto Martini¹ and Hermine I. Brunner², ¹PRINTO-IRCCS, Genova, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO-IRCCS, Genoa, Italy, ⁴Hôpital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Approximately 10-15% of patients (pts) with juvenile idiopathic arthritis (JIA) experience comorbid uveitis. The objective of this study is to explore events of uveitis and…
Abstract Number: 417 • 2016 ACR/ARHP Annual Meeting
Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis
Bessie Frias¹, Courtney McCracken², Kirsten Jenkins³, Janet Figueroa⁴, Anna Tramposch¹, Steven Yeh⁵, Purnima Patel⁴, Carolyn Drews-Botsch⁶, Sampath Prahalad^7,8 and Sheila Angeles-Han^2,7, ¹Emory University, Atlanta, GA, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁷Children's Healthcare of Atlanta, Atlanta, GA, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Pediatric HLA-B27-associated uveitis is a common form of non-infectious uveitis (NIU) that can lead to ocular complications and vision loss. Methotrexate (MTX) is the…
Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Hermine I. Brunner¹, Nicolino Ruperto², Vladimir Keltsev³, Ekaterina Alexeeva⁴, Carlos Abud-Mendoza⁵, Heinrike Schmeling⁶, María del Rocío Maldonado-Velázquez⁷, Nadina Rubio-Pérez⁸, Marina Stanislav⁹, Vyacheslav Chasnyk¹⁰, Diane Brown¹¹, Michael Henrickson¹, Daniel Kingsbury¹², C. Egla Rabinovich¹³, Andrew Zeft¹⁴, Earl Silverman¹⁵, Maggie Wang¹⁶, Philippa Charlton¹⁶, Rocio Lledo-Garcia¹⁷, Laura Shaughnessy¹⁶, Daniel J. Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Gaslini, Genoa, Italy, ³Togliatti City Clinical Hospital №5, Togliatti, Russian Federation, ⁴Children's Health of RAMS and IM Sechenov First Moscow State Medical University, Moscow, Russian Federation, ⁵Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁶Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁷Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁸Universidad Autónoma de Nuevo León, Nuevo León, Mexico, ⁹Research Rheumatology Institute V.A. Nassonova, Moscow, Russia, ¹⁰St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ¹¹Division of Rheumatology, Children's Hospital of Los Angeles and University of Southern California, Los Angeles, CA, ¹²Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹³Duke University Medical Center, Durham, NC, ¹⁴Cleveland Clinic, Pediatric Rheumatology, Cleveland, OH, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶UCB Pharma, Raleigh, NC, ¹⁷UCB Pharma, Slough, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…
Abstract Number: 112 • 2016 ACR/ARHP Annual Meeting
Leveraging a Learning Network to Implement and Standardize Self-Management Support into Care Delivery: Experience of Pediatric Rheumatology Care and Outcomes Improvement Network
Janalee Taylor¹, Avani Modi², Kristin Loiselle², Julie Gomez³, Karla B. Jones⁴, Sheetal S. Vora⁵, Julia Harris⁶, Beth Gottlieb⁷, Lisa Robbins⁸, Tzielan Lee⁹, Kristi Whitney-Mahoney¹⁰, Murray Passo¹¹, Melanie Kohlheim¹², Laura Curtis¹², Anjie Vago¹³, Kerry Ferraro¹², Kate Trevey¹², Jennifer Gil¹², Laura Bouslaugh¹², Angela Young¹², Nancy Griffin¹⁴, Anne Paul¹⁵, Carole M. Lannon¹⁴ and Esi Morgan¹⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Nationwide Children's, Columbus, OH, ⁵Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁸Penn State Hershey Children's Hospital, Hershey, PA, ⁹Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹³Pediatric Rheumatology Care and Outcomes Improvement Network, cincinnati, OH, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Disease outcomes can depend, to a large extent, on one’s ability to manage their condition effectively. For children with JIA this means managing oral,…
Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
DJ Lovell¹, N Ruperto², N Tzaribachev³, G Vega-Cornejo⁴, I Louw⁵, A Berman^6,7, I Calvo⁸, R Cuttica⁹, G Horneff¹⁰, F Avila-Zapata¹¹, J Anton¹², R Cimaz¹³, E Solau-Gervais¹⁴, R Joos¹⁵, G Espada¹⁶, X Li¹⁷, M Nys¹⁸, R Wong¹⁷, S Banerjee¹⁷, Hermine I. Brunner¹⁹, A Martini²⁰ and For Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology Collaborative Study Group (PRCSG), ¹Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴Clinica de Rheumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁵Panorama Medical Centre, Cape Town, South Africa, ⁶Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁸Hospital Univ. La Fe, Valencia, Spain, ⁹Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ¹⁰Centre Paediatric Rheumatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹¹Star Medica Hospital, Merida, Mexico, ¹²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁴Hôpital de la Miletrie, Poitiers, France, ¹⁵University Hospital Gent, Gent, Belgium, ¹⁶Cramer 1853 4°C, Hospital de Ninos Dr Ricardo Gutierrez, Buenos Aires, Argentina, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…
Abstract Number: 335 • 2016 ACR/ARHP Annual Meeting
High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis
Hiranda Dodanwala¹, Danielle Feger¹, Nicholas Longson², Nancy J. Olsen³, Barbara E. Ostrov^4,5 and Rayford R. June⁶, ¹Medicine - Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²Johns Hopkins University, Baltimore, MD, ³Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, ⁶Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritides. JIA is the most common cause of musculoskeletal disability in children, and…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 376 • 2016 ACR/ARHP Annual Meeting
Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease
Esi Morgan¹, Constance Mara², Bin Huang³, Adam Carle⁴, Kenneth Goldschneider⁵, Carlton Dampier⁶ and Susmita Kashikar-Zuck⁷, ¹Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ⁷Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The Patient Reported Outcomes Measurement Information System(PROMIS) is a publicly available assessment system offering multiple measures to assess physical, mental and social health.…
Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Sunil Sampath^1,2, Liza J. McCann³, Michael W. Beresford^3,4, Eileen Baildam³, Jamie C Sergeant^1,5, Wendy Thomson², Helen Foster⁶, Sharon Douglas², Taunton Southwood⁷, Kimme L. Hyrich¹ and Biologics for Children with Rheumatic Diseases (BCRD) study Group¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁷School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…
Abstract Number: 1289 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Parameters and PET/MRI in Juvenile Idiopathic Arthritis
Kathleen Jo Corbin¹, Emily von Scheven¹, Youngho Seo², Spencer Behr² and John MacKenzie³, ¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ²Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ³Section of Pediatric Radiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA
Background/Purpose: Positron emission tomography (PET) can be used to identify inflammation using 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG uptake correlates with clinical and laboratory markers of disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.